Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01093846) was an extension study involving people with Behçet's disease who had certain types of eye inflammation (uveitis — swelling inside the eye). A total of 59 participants were enrolled across three groups: 19 received injections of AIN457 (secukinumab) every two weeks, 18 received it once a month, and 22 received a placebo (a dummy injection with no active medicine). The trial was designed to measure whether continuous treatment with AIN457 reduced the rate of recurring eye flare-ups compared to the placebo. The reported data shows that the study was ended early before it was completed. Because of this early termination, no results for the primary outcome — the rate of recurring eye flare-ups — were ever analysed or reported. The ClinicalTrials.gov record notes that only safety-related information (records of side effects and adverse events) was collected and summarised, but those figures are not included in the outcomes section of the structured results. The number of participants who completed the study was very low, with only one person in the placebo group recorded as having fully completed it, and none in either AIN457 group. The reported data shows no efficacy (treatment effect) numbers are available from this trial due to its early closure. Any safety data that was gathered is noted as existing separately but was not provided in the structured results submitted here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Based on the information provided, the eligibility criteria fields appear to be empty — no inclusion or exclusion criteria were listed in the source text.
Here is what I can provide:
"Who might be able to join this trial:
- No specific inclusion criteria were listed in the provided information (confirm with trial site)
Who may not be able to join:
- No specific exclusion criteria were listed in the provided information (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying."
Please note: Since no eligibility details were included in the source text, it is especially important that you contact the trial site directly for NCT01093846. You can find full and up-to-date details by searching for NCT01093846 on ClinicalTrials.gov, where the complete eligibility criteria should be listed.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The Effect of Continuous Treatment With Subcutaneous AIN457 Compared to Placebo in Reducing the Rate of Recurrent Ocular Exacerbations in Behçet's Patients With Intermediate Uveitis, Posterior Uveitis or Panuveitis in Group 1.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.